ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

voclosporin

Also written as “LX211”, “Voclosporin” and “LUPKYNIS”.

Its studies are mostly in Lupus Nephritis · Psoriasis · Keratoconjunctivitis Sicca · Uveitis, Posterior · Glomerulosclerosis, Focal Segmental, led by 3 companies.

Drug pageVoclosporin: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 13, 202623 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aurinia Pharmaceuticals171 open or runningphase 4since May 13, 2026Oct 25, 2005Mar 2, 2029phase 4 · NCT07611214
Lux Biosciencesits history only50 open or runningphase 3since Nov 27, 2006Nov 27, 2006none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 3since Mar 20, 2024Mar 20, 2024Jun 2027phase 3 · NCT06406205

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aurinia Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Oct 25, 2005.

  1. Dec 4, 2006Phase 3 study in PsoriasisNCT00408187 · 642 enrolled · Canada, Germany, Poland
  2. Apr 25, 2012Phase 3 study in Renal TransplantationNCT01586845
  3. May 14, 2014Phase 2 study in Lupus NephritisNCT02141672 · 265 enrolled · United States, Bangladesh, Belarus and more
  4. Oct 20, 2016Phase 1 study in VolunteersNCT02949999 · 40 enrolled · Philippines
  5. Oct 26, 2016Phase 2 study in Lupus NephritisNCT02949973 · 10 enrolled · Malaysia
  6. Jan 12, 2017Phase 3 study in Lupus NephritisNCT03021499 · 358 enrolled · United States, Argentina, Belarus and more
  7. Jun 14, 2018Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT03598036 · 5 enrolled · United States, Dominican Republic
  8. Jun 25, 2018Phase 3 study in Lupus NephritisNCT03597464 · 216 enrolled · United States
  9. Jul 13, 2018Phase 2 study in Dry Eye SyndromesNCT03597139 · 100 enrolled · United States
  10. Oct 30, 2019Phase 3 study in Dry Eye SyndromesNCT04147650 · 508 enrolled · United States
  11. Feb 7, 2022Phase 1 study in Drug-drug InteractionNCT05306379 · 24 enrolled · United States
  12. Mar 11, 2022Phase 3 study in Lupus NephritisNCT05288855 · 9 enrolled · United States, Colombia, Japan and more
  13. Jun 21, 2023Phase 3 study in Lupus NephritisNCT05962788 · 4 enrolled · United States, Colombia, Japan and more
  14. May 13, 2026Phase 4 study in Lupus NephritisNCT07611214 · 150 planned · United States

Ahead

  1. Mar 2, 2029Primary completion: phase 4 study in Lupus NephritisNCT07611214

TargetBeta

PPP3CA →read by rule
“Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor”ChEMBL 37, by rule

Studies

All 17 Aurinia Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07611214Lupus Nephritis · United States4RecruitingMar 2, 2029150
NCT05962788Lupus Nephritis · United States, Colombia, Japan and more3TerminatedJul 4, 20254
NCT05288855Lupus Nephritis · United States, Colombia, Japan and more3TerminatedJul 3, 20259
NCT05306379Drug-drug Interaction · United States1CompletedApr 5, 202224
NCT04147650Dry Eye Syndromes · United States3CompletedSep 17, 2020508
NCT03597139Dry Eye Syndromes · United States2CompletedNov 9, 2018100
NCT03597464Lupus Nephritis · United States3CompletedOct 7, 2021216
NCT03598036Glomerulosclerosis, Focal Segmental · United States, Dominican Republic2TerminatedMay 19, 20205
NCT03021499Lupus Nephritis · United States, Argentina, Belarus and more3CompletedSep 24, 2019358
NCT02949973Lupus Nephritis · Malaysia2CompletedDec 201610
NCT02949999Volunteers · Philippines1CompletedDec 201640
NCT02141672Lupus Nephritis · United States, Bangladesh, Belarus and more2CompletedJul 2016265
NCT01586845Renal Transplantation3WithdrawnDec 20150
NCT00408187Psoriasis · Canada, Germany, Poland3CompletedDec 2008642
NCT00270634Kidney Diseases · United States, Canada2CompletedJul 2009334
NCT00258713Psoriasis · Canada3CompletedJul 2006309
NCT00244842Psoriasis · Canada3CompletedOct 2005451

How it is read

Names in the registry

  • “LX211”, 10 entries
  • “Voclosporin”, 7 entries
  • “voclosporin”, 6 entries
  • “LUPKYNIS”, 1 entry
  • “Voclosporin(QL1074)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.